| Nov 18 |
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
|
| Nov 14 |
Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans
|
| Nov 13 |
Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028
|
| Nov 12 |
Apogee Therapeutics reports Q3 results
|
| Nov 12 |
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
|
| Nov 10 |
Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
|
| Nov 4 |
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
|
| Oct 24 |
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
|
| Oct 16 |
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
|
| Oct 7 |
Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now
|
